Dr. Ashish Pershad, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3420 S Mercy Rd Ste 312, Gilbert, AZ 85297 Phone: 480-728-6400 Fax: 480-728-6440 |
Michael D. Barry, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3420 S Mercy Rd, Suite 300, Gilbert, AZ 85297 Phone: 480-955-0900 Fax: 480-955-0800 |
Dr. Gautam Kedia, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3011 S Lindsay Rd, Suite 105, Gilbert, AZ 85295 Phone: 480-699-5536 Fax: 480-699-9283 |
Bashar J Markabawi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3011 S Lindsay Rd, Suite 105, Gilbert, AZ 85295 Phone: 480-699-5536 Fax: 480-699-9283 |
Dr. Mohammad Reza Hojjati, M.D., PHD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2680 S Val Vista Dr Ste 187, Gilbert, AZ 85295 Phone: 480-476-8750 Fax: 480-476-8749 |
Khaled Albasha, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3505 S Mercy Rd, Gilbert, AZ 85297 Phone: 480-786-9100 |
News Archive
The discovery that the Lag-3 gene acts as a brake to prevent immune system responses from running out of control solves a mystery that has puzzled researchers since the gene was discovered 14 years ago.
Estimates are that some 10 percent of people over the age of 65 will develop Alzheimer's disease, the scourge that robs people of their memories and, ultimately, their lives.
Researchers from Osaka University have described the link between accurate protein folding and misfolding that can lead to the formation of amyloid fibers, which are implicated in neurodegenerative diseases
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.
Transwestern today announces it has been named one of five finalists in the 2015 NJBIZ Healthcare Heroes awards program. Nominated in the "Workplace Wellness Hero" category, Transwestern is being recognized for its company-wide wellness program and efforts to promote a healthy work environment.
› Verified 1 days ago